Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/TAKEDA-PHARMACEUTICAL-COM-6491073/news/Takeda-Announces-China-NMPA-Approval-of-LIVTENCITY-for-the-Treatment-of-Adults-with-Post-transplant-45625557/?utm_source=whatsapp&utm_medium=social&utm_campaign=share